№ files_lp_4_process_1_46238
File format: docx
Character count: 2927
File size: 267 KB
Regulatory prescribing guidance outlining authorised prescribers, approved medical conditions, specialist requirements, patient age criteria, maximum stimulant dosages and notification procedures under the Western Australia Department of Health.
Jurisdiction:
Western Australia, Australia
Responsible authority:
Department of Health
Subject:
Prescribing of stimulant medicines
Document type:
Prescribing guidance / regulatory information
Target users:
Medical practitioners authorised to prescribe stimulant medicines
Approved conditions:
ADHD; Acquired brain injury; Depression; Narcolepsy; Binge eating disorder
Approved specialists:
Paediatrician; Neurologist; Paediatric neurologist; Psychiatrist; Child and adolescent psychiatrist; Rehabilitation physician; Paediatric rehabilitation physician; Respiratory and sleep physician; Thoracic medicine physician
Patient eligibility:
Patients within specified approved age criteria depending on prescriber specialisation
Minimum patient age:
4 years (for child-specialist prescribers)
Maximum stimulant doses:
Dexamfetamine up to 60 mg/day; Lisdexamfetamine up to 70 mg/day; Methylphenidate up to 120 mg/day; combination doses calculated as dexamfetamine equivalents
Prescription setting:
Clinical treatment of approved conditions
Regulatory requirement:
Notification to the Department of Health when commencing stimulant treatment or when specified patient or prescriber details change
Co-prescriber rules:
Co-prescribers must be medical practitioners practising in Western Australia and recorded in the notification
Review requirement:
Annual patient review by the primary stimulant prescriber
Contact service:
Schedule 8 Medicines Prescriber Information Service
Telehealth provision:
Interstate practitioners may prescribe via telehealth for Western Australian residents for prescriptions issued on or after 13 December 2023
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
United States
Topic:
Stimulant use disorder, clinical guidelines
Document Type:
Clinical Practice Guideline
Organization / Institution:
ASAM, AAAP
Author:
Not specified
Target Audience:
Healthcare professionals, addiction specialists
Effective Period:
Not specified
Approval Date:
2021
Date of Revisions:
Not specified
Year:
2023
Region / City:
Massachusetts
Topic:
Opioid Use Disorder, Medication Comparison
Document Type:
Clinical Guidelines
Organization / Institution:
Massachusetts Department of Public Health, Bureau of Health Care Safety & Quality
Author:
Massachusetts Department of Public Health
Target Audience:
Healthcare providers, Long-Term Care Facilities
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / city:
South East London
Topic:
Shared care prescribing for narcolepsy and idiopathic hypersomnia treatment
Document type:
Medical guideline
Organization / institution:
South East London Interface Prescribing Policy
Author:
Specialist clinicians, GP teams
Target audience:
Healthcare professionals, GPs, specialists
Period of validity:
Ongoing until updated
Approval date:
Not specified
Date of amendments:
Not specified
Author:
Shawnee Dixon
Title:
ADHD Medication
Course:
Drugs, Behavior and Modern Science
Type of document:
Research Paper
Date:
August 9, 2014
Subject:
Attention Deficit Hyperactivity Disorder and prescription stimulant abuse
Key topics:
ADHD diagnosis, stimulant medications, nonmedical use, emergency department visits, side effects
Institutions referenced:
National Institute of Mental Health (NIMH); Centers for Disease Control and Prevention (CDC); National Institute of Drug Abuse (NIH); Drug Abuse Warning Network (DAWN)
Medications discussed:
amphetamine; methylphenidate; atomoxetine; lisdexamfetamine dimesylate; dextroamphetamine; methamphetamine hydrochloride
Population focus:
Children and adolescents ages 3–17; individuals using prescription stimulants nonmedically
Geographical context:
United States
Sources cited:
NIMH (2013–2014); CDC (2013); NIH (2014); DAWN (2004, 2008); American Journal of Health-System Pharmacy (2014)
Year:
No specific year mentioned
Region / City:
No specific region or city mentioned
Topic:
Cocaine use and its effects
Document Type:
Health and safety guide
Agency / Institution:
No specific agency or institution mentioned
Author:
No author specified
Target Audience:
General public, individuals seeking information on cocaine and its effects
Period of Validity:
No specific period mentioned
Approval Date:
No approval date mentioned
Date of Changes:
No date of changes mentioned
Document title:
Protocol for the adjustment of insulin doses in diabetes
Organisation:
Aneurin Bevan University Health Board
Service area:
Adult Diabetes Service
Type of document:
Clinical protocol
Target population:
Adults with diabetes
Clinical setting:
Acute and community settings
Intended users:
Diabetes dietitians within the multidisciplinary team
Author:
Elaine Hibbert-Jones
Contributors:
Francesca Annan; Dorothy Debrah; Neera Agarwal; Kathryn John
Responsible committee:
Medicines Management
Geographical scope:
Wales
Insulin preparations:
Aneurin Bevan Drug Formulary
Exclusions:
Inpatients; pregnancy; paediatrics; insulin pump therapy without additional training
Date issued:
May 2018
Review date:
May 2021
Key topics:
Insulin dose adjustment; hypoglycaemia; hyperglycaemia; blood glucose monitoring; basal and bolus insulin; injection technique
Year:
2020
Region / city:
Australia
Topic:
Medical Submission for Pharmaceutical Product
Document Type:
Submission
Organization / Institution:
Chiesi Australia Pty Ltd
Author:
Chiesi Australia Pty Ltd
Target Audience:
Medical professionals, regulatory authorities
Period of validity:
Not specified
Approval Date:
June 24, 2020
Date of changes:
Not specified
Year:
2019
Region / City:
Australia
Topic:
Hormone Replacement Therapy (HRT)
Document Type:
Regulatory Submission
Organization / Institution:
Besins Healthcare Australia Pty Ltd
Author:
Not specified
Target Audience:
Health professionals and regulatory authorities
Period of Effectiveness:
Not specified
Approval Date:
8 May 2019
Modification Date:
Not specified
Registration Status:
TGA Registered
Indications:
Estrogen deficiency, prevention of osteoporosis, menstrual irregularities, hormone replacement therapy
Purpose:
Request for listing of medications in General Schedule
Product Names:
Estrogel®, Prometrium®, Estrogel Pro
Safety Data:
Includes safety outcomes such as breast pain, tenderness, breakthrough bleeding, and breast cancer risk
Comparator Products:
Sandrena®, MPA (medroxyprogesterone acetate)
Clinical Claims:
Efficacy and safety comparison of Estrogel and MP to Sandrena and MPA
Source:
Tables 1.2, pp23-24
Year:
2026
Region / City:
Not specified
Subject:
Chemical risk assessment, toxicology
Document Type:
Supplemental tables
Institution / Agency:
Not specified
Author:
Not specified
Exposure Routes:
Oral, Inhalation
Exposure Duration:
Acute, Intermediate, Chronic
Data Type:
Quantal, Continuous, Not applicable
Chemicals Included:
Chromium (VI), 1,1,2,2-Tetrachloroethane, 1,3-Dichloropropene, Cresols, Ethylene Glycol, Tris(2-Chloroethyl) Phosphate, Tributyl Phosphate, Tris(2-Butoxyethyl) Phosphate, Tris(1,3-Dichloro-2-Propyl) Phosphate, Monomethylarsonic Acid, Dimethylarsinic Acid, Acrylamide, Toxaphene, Uranium, 2-Methylnaphthalene, Barium Salts, Boron Compounds, Cadmium, Vanadium Compounds, Benzene, 1,3 Butadiene, Polybrominated Diphenyl Ethers, Sulfur Mustard, Ethylbenzene, Toluene, Xylenes
MRL Values:
Listed per chemical in mg/kg/day or mg/m³ or ppm
Risk Levels:
K=1, Upper Bound Risk, Relative Risk Ratios (RR) at 2x and 5x MRL
Benchmark Dose Type:
BMD, BMDL, BMCL, LOAEL
Year:
2021
Region / city:
Nepal
Topic:
Public health / Covid-19 vaccination
Document type:
Urgent action / appeal letter
Organization:
Amnesty International
Author:
Not specified
Target audience:
International community, governments with vaccine surplus
Action deadline:
17 August 2021
Vaccine involved:
Oxford-AstraZeneca
Population affected:
Over 1.4 million high-risk individuals
First dose period:
7–15 March 2021
Required second dose period:
27 June–5 July 2021
Vaccination coverage at time of report:
2.4% fully vaccinated
Urgent needs:
Immediate vaccine delivery, international support, TRIPS waiver advocacy
Year:
2020
Region / City:
Georgia
Topic:
Environmental Education, Outdoor Learning
Document Type:
Toolkit
Organization / Institution:
Environmental Education Alliance (EEA)
Author:
Environmental Education Alliance (EEA)
Target Audience:
Environmental educators, K-12 school teachers, school district administrators, outdoor learning specialists
Period of Action:
2020
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2026
Region / City:
Wisconsin
Topic:
Elder Benefit Specialist Program
Document Type:
Checklist
Agency / Institution:
Wisconsin Department of Health Services
Author:
Unknown
Target Audience:
New Elder Benefit Specialists
Effective Period:
First year of employment
Approval Date:
Unknown
Date of Changes:
Unknown
Year:
N/A
Region / City:
N/A
Topic:
Security requirements for leasing specialists
Document Type:
Guidelines
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Leasing specialists, security specialists, government contractors
Effective Period:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Contextual Description
Year:
2023
Region / city:
United Kingdom
Topic:
Fire safety, Disabled people, Grenfell Tower Inquiry
Document type:
Statement
Organisation:
Multiple organisations supporting Disabled people
Author:
Not specified
Target audience:
Government officials, Disabled people, Public
Period of validity:
Not specified
Approval date:
11 September 2023
Modification date:
Not specified
Note:
Year
Year:
N/A
Region / City:
N/A
Topic:
Vehicle procurement and fleet management
Document Type:
Process document
Institution / Organization:
Office of Vehicle Management
Author:
N/A
Target Audience:
Agency fleet managers, vehicle procurement staff
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Region / City:
Oregon
Topic:
Behavioral Health
Document Type:
Contact List
Agency / Institution:
Oregon Health Authority
Author:
Nirmala Dhar
Target Audience:
Behavioral Health Professionals, Older Adult Service Providers
Context:
List of contact details for specialists in the field of older adult behavioral health across various counties in Oregon.
Year:
2020
Region / city:
Australia
Topic:
Healthcare, General Practice, Medical Referrals
Document type:
Guide
Organization:
Australian Medical Association (AMA)
Author:
Australian Medical Association
Target audience:
General Practitioners (GPs), Healthcare Professionals
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified